ARCT - Arcturus: Biotech With Great Potential In Covid-19 Vaccine Space
- Phase 3 pivotal study succeeds in endpoints using ARCT-154 for Covid-19; Emergency Use Authorization submitted to Vietnam with possible approval for use in coming weeks/months.
- Ability to expand ARCT-154 in the Covid-19 booster treatment market space; Company already received feedback from several regulators for such a pivotal booster study for Covid-19.
- An ongoing study using ARCT-021 for Covid-19 can possibly establish additional proof of concept for self amplifying mRNA and LUNAR delivery technologies.
- Additional shots on goal in the pipeline include LUNAR-FLU for influenza, ARCT-810 for OTC Deficiency and ARCT-032 for Cystic Fibrosis.
For further details see:
Arcturus: Biotech With Great Potential In Covid-19 Vaccine Space